All News

Found 3,700 articles

• Ryvu Therapeutics Reports 2023 Half-Year Financial Results and Provides Corporate Update

  9/13/2023

  Ryvu Therapeutics reported financial results for the first half of 2023 and provided a corporate update.

• Henlius Expands Collaboration with KGbio to Develop, Commercialize and Supply Henlius' novel anti-PD-1 mAb HANSIZHUANG in MENA

  9/12/2023

  Shanghai Henlius Biotech, Inc. has entered into an exclusive license agreement with PT Kalbe Genexine Biologics, an Indonesian pharmaceutical company and a holding subsidiary to PT Kalbe Farma, Tbk, for the development and commercialisation of HANSIZHUANG as a treatment for two indications including ES-SCLC, Henlius' novel anti-PD-1 mAb, in 12 Middle East and North African countries including Saudi Arabia, the United Arab Emirates, Egypt, Qatar, Jordan, Morocco, etc.

• Sorrento Announces Phase 3 Trial Met Primary Endpoint and Key Secondary Endpoint in Mild or Moderate COVID-19 Adult Patients Treated with Ovydso (Olgotrelvir), an Oral Mpro Inhibitor as a Standalone Treatment for COVID-19

  9/12/2023

  Sorrento Therapeutics, Inc. (OTC: SRNEQ, “Sorrento”) announced today positive topline results of a pivotal Phase 3 study of Sorrento’s oral Mpro inhibitor, Ovydso (Olgotrelvir, STI-1558), in mild or moderate symptomatic adults infected with SARS-CoV-2, or COVID-19, irrespective of risk factors for severe complications.

• Myeloid Therapeutics Initiates Patient Dosing with MT-302, a Novel TROP2-Targeting RNA CAR, in Phase 1 Study for Advanced or Metastatic Epithelial Tumors

  9/12/2023

  Myeloid Therapeutics, Inc. ("Myeloid"), a clinical stage oncology company, has dosed the first patient with MT-302 in a Phase 1 study for advanced or metastatic epithelial tumors.

• Defence's Broad and Versatile Accum(R) Technology Platform Focus on Cancer Therapeutics

  9/12/2023

  Defence Therapeutics Inc. (CSE: DTC) (FSE: DTC) (OTC Pink: DTCFF) ("Defence" or the "Company"), one of the leading Canadian biotechnology companies, is pleased to announce its continuation to bringing innovative

• 

  Gilead’s Trodelvy Shows Potential as First-Line Treatment in NSCLC

  9/11/2023

  The first-in-class antibody-drug conjugate—in combination with Merck’s Keytruda—has shown promising results in a Phase II study of patients with metastatic non-small cell lung cancer.

• Pfizer and BioNTech Receive U.S. FDA Approval for 2023-2024 COVID-19 Vaccine

  9/11/2023

  Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced that the U.S. Food and Drug Administration (FDA) approved the supplemental Biologics License Application (COMIRNATY 2023-2024 Formulation) for individuals 12 years and older and granted emergency use authorization for individuals 6 months through 11 years of age for the companies’ Omicron XBB.1.5-adapted monovalent COVID-19 vaccine.

• ENHERTU® (fam-trastuzumab deruxtecan-nxki) Demonstrated Strong and Durable Tumor Responses in Previously Treated HER2-mutant Advanced Lung Cancer in DESTINY-Lung02 Phase II Trial

  9/11/2023

  AstraZeneca and Daiichi Sankyo’s Results from the primary analysis of the DESTINY-Lung02 Phase II trial showed ENHERTU® (fam-trastuzumab deruxtecan-nxki) continued to demonstrate strong and durable tumor responses in previously treated patients with HER2-mutant (HER2m) unresectable and/or metastatic non-squamous non-small cell lung cancer (NSCLC).

• Elucida Oncology Announces Abstract Accepted for Poster Presentation at ESMO Congress 2023

  9/11/2023

  Elucida Oncology, a clinical-stage biotechnology company pioneering the next frontier in targeted cancer therapy, announced today an abstract featuring ELU001, its lead C’Dot Drug Conjugate (CDC) clinical candidate, has been accepted for poster presentation at the ESMO Congress 2023 being held in Madrid, Spain from October 20-24, 2023.

• Ifinatamab Deruxtecan Continues to Demonstrate Durable Responses in Patients with Advanced Small Cell Lung Cancer in Early Trial

  9/10/2023

  Updated results from a subgroup analysis of a phase 1/2 trial showed that ifinatamab deruxtecan continues to demonstrate durable responses in patients with heavily pretreated advanced small cell lung cancer.

• 

  Seagen, Nurix Team to Create New Class of Antibody Conjugates for Cancer

  9/8/2023

  The companies have started a collaboration worth up to $3.4 billion to develop a portfolio of degrader-antibody conjugates, a potentially new class of antibodies that selectively kill cancer cells.

• Myricx Enters into Antibody License Agreement with Biocytogen

  9/8/2023

  Myricx Bio (‘Myricx’), a UK biotech company focusing on the discovery and development of a completely novel class of selective cytotoxic payloads for antibody drug conjugates (ADCs), today announces an antibody license agreement with Biocytogen Pharmaceuticals (Beijing) Co., Ltd (‘Biocytogen’, HKEX: 02315), a global biotech company focusing on the discovery of novel antibody therapeutics.

• Mabwell and WuXi XDC Sign Long-Term ADC Strategic Collaboration to Accelerate Global Layout of Innovative Biologics

  9/8/2023

  Mabwell, an innovative biopharmaceutical company with entire industry chain, and WuXi XDC, a leading global CRDMO, joint announced that they have signed a LOI for long-term strategic collaboration on Mabwell's multiple ADC projects.

• Sorrento Therapeutics Announces Positive Phase 2a Clinical Trial Results for Resiniferatoxin (RTX) for the Treatment of Knee Pain in Moderate to Severe Osteoarthritis of the Knee (OAK) Patients

  9/7/2023

  Sorrento Therapeutics, Inc. (OTC: SRNEQ, "Sorrento") announced today positive Phase 2a top-line clinical trial results for the RTX program.

• Biocytogen Enters into Antibody Evaluation, Option and License Agreement with Myricx for ADC Development

  9/7/2023

  Biocytogen Pharmaceuticals today announces an antibody evaluation, option and license agreement with Myricx Bio (‘Myricx’), a UK biotech company focusing on the discovery and development of a completely novel class of selective cytotoxic payloads for antibody drug conjugates (ADCs).

• ALX Oncology Realigns Executive Leadership Team

  9/6/2023

  ALX Oncology Holdings Inc. today announced that Jason Lettmann, a member of the Board of Directors, will succeed Jaume Pons, Ph.D. as Chief Executive Officer, effective September 6, 2023.

• BioAtla to Participate in the H.C. Wainwright 25th Annual Global Investment Conference

  9/6/2023

  BioAtla, Inc. today announced that the Company’s management will provide a corporate update and participate virtually in scheduled one-on-one investor meetings at the H.C. Wainwright 25th Annual Global Investment Conference, to be held September 11-13, 2023.

• Biohaven Announces Positive Data from its Exploratory Electroencephalogram (EEG) Biomarker Study of BHV-7000, Completion of Once-Daily Formulation Development, and Plan to Initiate Phase 3 Pivotal Studies

  9/5/2023

  Biohaven Ltd. announced preliminary analyses and positive biomarker data from Biohaven's exploratory Phase 1 electroencephalogram biomarker study, which was presented to epilepsy key opinion leaders at an off-site meeting held during the International Epilepsy Conference 2023 in Dublin, Ireland.

• Sparx Biopharmaceutical Welcomes Dr. Roland Meier as Chief Medical Officer

  9/5/2023

  Spearheading the field of powered antibody therapies, SparX Biopharmaceutical Corp. proudly announces the addition of Dr. Roland Meier as their esteemed Chief Medical Officer.

• Alteogen's Tergase® (Novel Recombinant Human Hyaluronidase Injection) Shows Excellent Immunogenicity Profile

  9/5/2023

  Alteogen Inc. (KOSDAQ:196170), a Korean biotech company announced that their recently concluded clinical trial of Tergase® showed zero incidence of ADA (including neutralizing antibodies).  Tergase® is Alteogen's first proprietary product currently under pharmaceutical approval process by the Korean Ministry of Food and Drug Safety.